Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
Sanofi is aiming to secure national immunization program (NIP) status in Japan for its anti-respiratory syncytial virus (RSV) antibody Beyfortus (nirsevimab) as early as 2026, a move the company says would make the preventive drug accessible to all newborns and…
To read the full story
Related Article
- Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
- Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
July 22, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib
January 27, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
BUSINESS
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Alfresa Launches End-to-End Platform to Support Biotech Entry into Japan
February 2, 2026
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…